Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1983 1
1984 1
1985 1
1987 3
1988 2
1989 5
1990 13
1991 29
1992 48
1993 79
1994 105
1995 75
1996 105
1997 107
1998 104
1999 123
2000 116
2001 92
2002 113
2003 105
2004 87
2005 114
2006 101
2007 89
2008 99
2009 101
2010 114
2011 94
2012 87
2013 113
2014 122
2015 142
2016 171
2017 181
2018 162
2019 219
2020 226
2021 254
2022 307
2023 320
2024 388
2025 565
2026 341

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,136 results

Results by year

Filters applied: . Clear all
Page 1
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.
Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Reyes-Soffer G, et al. Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60. doi: 10.1161/ATV.0000000000000147. Epub 2021 Oct 14. Arterioscler Thromb Vasc Biol. 2022. PMID: 34647487 Free PMC article. Review.
High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis. Lp …
High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for …
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
Hoogeveen RC, Ballantyne CM. Hoogeveen RC, et al. Clin Chem. 2021 Jan 8;67(1):143-153. doi: 10.1093/clinchem/hvaa252. Clin Chem. 2021. PMID: 33257928 Free PMC article. Review.
Although statins do not generally lower lipoprotein(a), proprotein convertase subtilisin/kexin type 9 inhibitors reduce lipoprotein(a) and cardiovascular outcomes, and newer approaches are in development. ...Growing evidence supports a causal ro …
Although statins do not generally lower lipoprotein(a), proprotein convertase subtilisin/kexin type 9 inhibitors reduce lip …
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS. O'Donoghue ML, et al. Circulation. 2019 Mar 19;139(12):1483-1492. doi: 10.1161/CIRCULATIONAHA.118.037184. Circulation. 2019. PMID: 30586750 Free article. Clinical Trial.
However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined. METHODS: Lp(a) was measured in 25 096 patients in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subje …
However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined. METHODS …
Lipoprotein(a) and cardiovascular disease.
Nordestgaard BG, Langsted A. Nordestgaard BG, et al. Lancet. 2024 Sep 28;404(10459):1255-1264. doi: 10.1016/S0140-6736(24)01308-4. Epub 2024 Sep 12. Lancet. 2024. PMID: 39278229 Review.
One in five people are at high risk for atherosclerotic cardiovascular disease and aortic valve stenosis due to high lipoprotein(a). ...Concentrations are more than 90% genetically determined and 17% higher in post-menopausal women than in men. …
One in five people are at high risk for atherosclerotic cardiovascular disease and aortic valve stenosis due to high …
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Kronenberg F, et al. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361. Eur Heart J. 2022. PMID: 36036785 Free PMC article.
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, provides clinical guidance for testing and treatin …
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) i …
Lipoprotein(a) as a cardiovascular risk factor: current status.
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Nordestgaard BG, et al. Eur Heart J. 2010 Dec;31(23):2844-53. doi: 10.1093/eurheartj/ehq386. Epub 2010 Oct 21. Eur Heart J. 2010. PMID: 20965889 Free PMC article.
AIMS: The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and, second, to advise on screening for elevated plasma Lp(a), on desirable levels, and on therapeutic strategies. METHODS AND RESULT …
AIMS: The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk …
Lipoprotein(a): cardiovascular risk and emerging therapies.
Fujino M, Nicholls SJ. Fujino M, et al. Expert Rev Cardiovasc Ther. 2023 Apr;21(4):259-268. doi: 10.1080/14779072.2023.2197593. Epub 2023 Apr 3. Expert Rev Cardiovasc Ther. 2023. PMID: 37010028 Review.
INTRODUCTION: There is abundant evidence that elevated lipoprotein(a) [LP(a)] associates with cardiovascular risk. Most lipid modifying therapies don't reduce Lp(a), but new technologies are emerging that act upstream, such as antisense oligonucleotide …
INTRODUCTION: There is abundant evidence that elevated lipoprotein(a) [LP(a)] associates with cardiovascular risk …
Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.
Small AM, Pournamdari A, Melloni GEM, Scirica BM, Bhatt DL, Raz I, Braunwald E, Giugliano RP, Sabatine MS, Peloso GM, Marston NA, Natarajan P. Small AM, et al. JAMA Cardiol. 2024 Apr 1;9(4):385-391. doi: 10.1001/jamacardio.2023.5605. JAMA Cardiol. 2024. PMID: 38353970 Free PMC article. Clinical Trial.
IMPORTANCE: Elevated lipoprotein(a) (Lp[a]) is a putative causal risk factor for atherosclerotic cardiovascular disease (ASCVD). There are conflicting data as to whether Lp(a) may increase cardiovascular risk only in the presence o …
IMPORTANCE: Elevated lipoprotein(a) (Lp[a]) is a putative causal risk factor for atherosclerotic cardiovascular …
Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week.
Tsimikas S, Marcovina SM. Tsimikas S, et al. J Am Coll Cardiol. 2022 Aug 30;80(9):934-946. doi: 10.1016/j.jacc.2022.06.019. J Am Coll Cardiol. 2022. PMID: 36007992 Free article. Review.
This study reviews ancestral differences in the genetics of the LPA gene, risk categories of elevated lipoprotein(a) [Lp(a)] as defined by guidelines, ancestry-specific Lp(a) risk, absolute and proportional risk, predictive value of risk …
This study reviews ancestral differences in the genetics of the LPA gene, risk categories of elevated lipoprotein(a) [L …
Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk.
Volgman AS, Koschinsky ML, Mehta A, Rosenson RS. Volgman AS, et al. J Am Heart Assoc. 2024 Jun 18;13(12):e033654. doi: 10.1161/JAHA.123.033654. Epub 2024 Jun 15. J Am Heart Assoc. 2024. PMID: 38879448 Free PMC article. Review.
Elevated lipoprotein(a) is a genetically transmitted codominant trait that is an independent risk driver for cardiovascular disease. ...Herein, we discuss the genetic determinants of lipoprotein(a) levels, explore the pathophysiolo …
Elevated lipoprotein(a) is a genetically transmitted codominant trait that is an independent risk driver for cardiov …
5,136 results